Organization
GSK Faces Major Setback in Zantac Litigation as Judge Allows Over 70,000 Lawsuits to Proceed
GSK, Zantac, Lawsuits, Cancer, Delaware Court, Judge Vivian Medinilla, Ranitidine, NDMA, Pharmaceuticals
CSL Seqirus Secures Fourth US Award to Enhance Bird Flu Vaccine Stockpile
CSL Seqirus, bird flu vaccine, US government award, BARDA, pandemic preparedness, avian influenza, H5N1, vaccine stockpile, public health protection
Palleos Healthcare and OCT Global Unite to Form Comprehensive European Contract Research Organization ###
Palleos Healthcare, OCT Global, European CRO, Merger, Clinical Research, Contract Research Organization
BIO Undergoes Transformative Restructuring for Future Growth
BIO, lobbying group, reorganization, restructuring, layoffs, future growth, transformation, biotechnology industry.
Revolutionizing Drug Discovery: Sanofi, OpenAI, and Formation Bio Join Forces
Sanofi, OpenAI, Formation Bio, AI, drug development, partnership, drug discovery, pharmaceuticals, artificial intelligence, healthcare innovation.
Legislators Profit from Bill Restricting Chinese Biotech Firms
Congress, stock trading, China biotech ban, financial gain, legislative influence, conflict of interest.
Translarna by PTC Therapeutics: Awaiting Another EU Regulatory Review for Muscular Dystrophy Treatment
PTC Therapeutics, Translarna, muscular dystrophy, EU review, regulatory approval, Duchenne muscular dystrophy (DMD), European Medicines Agency (EMA), ataluren, rare disease treatment.
EMA Recommends Halt on Preterm Birth Medications Due to Safety Concerns
European Medicines Agency (EMA), safety committee, preterm birth drugs, suspension, safety concerns, pregnancy, fetal development.
Galapagos Expands Decentralized CAR-T Manufacturing Across the Nation with Strategic Partnership
Galapagos, decentralized CAR-T manufacturing, partnership, nationwide expansion, cancer treatment, immunotherapy, biotechnology, healthcare innovation.
Maze Therapeutics Secures New Partnership for Pompe Drug Development After Sanofi Deal Collapse
Maze Therapeutics, Pompe drug, partnership, Sanofi deal collapse, drug development, genetic diseases